Compare Sirius XM Holdings Inc (SIRI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs BIO-TECHNE Corp — how do they compare? Sirius XM Holdings Inc trades at $26.68 (market cap $8.75B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Sirius XM Holdings Inc pays the higher dividend (4.16%). Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and BIO-TECHNE Corp for 63 Days on average.
| SIRI | TECH | |
|---|---|---|
Market Cap | $8.75B | $11.37B |
Volume | 4,004,963 | 3,153,511 |
Sector | Media | Health |
52-Week High | $32.59 | $72.61 |
52-Week Low | $19.92 | $43.31 |
Typical Hold Time | 102 Days | 63 Days |
Enterprise Value | $18.03B | $11.40B |
Dividend Yield | 4.16% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.33, down 0.11% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 10.42 and P/B of 0.73 indicating potential undervaluation, while recent quarterly earnings have been inconsistent with two misses and one beat. Cash flow trends show improvement with projected positive net cash flow of $82 million in 2026. Recent news highlights strategic partnerships with YouTube and institutional buying activity.
The stock presents a value opportunity with analyst consensus price target of $34.43 (31% upside) and 62.5% buy ratings. Key risks include competitive pressures in audio streaming and execution challenges in advertising expansion. The YouTube partnership could drive EBITDA growth, but inconsistent earnings performance remains a concern for investors.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
